Myeloid cell-targeted therapies for solid tumours.
Journal
Nature reviews. Immunology
ISSN: 1474-1741
Titre abrégé: Nat Rev Immunol
Pays: England
ID NLM: 101124169
Informations de publication
Date de publication:
02 2023
02 2023
Historique:
accepted:
12
05
2022
pubmed:
14
6
2022
medline:
4
2
2023
entrez:
13
6
2022
Statut:
ppublish
Résumé
Myeloid cells are the most abundant immune components of the tumour microenvironment, where they have a variety of functions, ranging from immunosuppressive to immunostimulatory roles. The myeloid cell compartment comprises many different cell types, including monocytes, macrophages, dendritic cells and granulocytes, that are highly plastic and can differentiate into diverse phenotypes depending on cues received from their microenvironment. In the past few decades, we have gained a better appreciation of the complexity of myeloid cell subsets and how they are involved in tumour progression and resistance to cancer therapies, including immunotherapy. In this Review, we highlight key features of monocyte and macrophage biology that are being explored as potential targets for cancer therapies and what aspects of myeloid cells need a deeper understanding to identify rational combinatorial strategies to improve clinical outcomes of patients with cancer. We discuss therapies that aim to modulate the functional activities of myeloid cell populations, impacting their recruitment, survival and activity in the tumour microenvironment, acting at the level of cell surface receptors, signalling pathways, epigenetic machinery and metabolic regulators. We also describe advances in the development of genetically engineered myeloid cells for cancer therapy.
Identifiants
pubmed: 35697799
doi: 10.1038/s41577-022-00737-w
pii: 10.1038/s41577-022-00737-w
doi:
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
106-120Informations de copyright
© 2022. Springer Nature Limited.
Références
Chen, D. S. & Mellman, I. Oncology meets immunology: the cancer-immunity cycle. Immunity 39, 1–10 (2013).
doi: 10.1016/j.immuni.2013.07.012
Sharma, P. et al. The next decade of immune checkpoint therapy. Cancer Discov. 11, 838–857 (2021).
doi: 10.1158/2159-8290.CD-20-1680
Rosenberg, S. A. & Restifo, N. P. Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348, 62–68 (2015).
doi: 10.1126/science.aaa4967
Pitt, J. M. et al. Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and -extrinsic factors. Immunity 44, 1255–1269 (2016).
doi: 10.1016/j.immuni.2016.06.001
Sharma, P., Hu-Lieskovan, S., Wargo, J. A. & Ribas, A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168, 707–723 (2017).
doi: 10.1016/j.cell.2017.01.017
DeNardo, D. G. & Ruffell, B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 19, 369–382 (2019).
doi: 10.1038/s41577-019-0127-6
Engblom, C., Pfirschke, C. & Pittet, M. J. The role of myeloid cells in cancer therapies. Nat. Rev. Cancer 16, 447–462 (2016).
doi: 10.1038/nrc.2016.54
DeNardo, D. G. et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 1, 54–67 (2011).
doi: 10.1158/2159-8274.CD-10-0028
Wang, T. et al. BRAF inhibition stimulates melanoma-associated macrophages to drive tumor growth. Clin. Cancer Res. 21, 1652–1664 (2015).
doi: 10.1158/1078-0432.CCR-14-1554
Kumagai, S., Koyama, S. & Nishikawa, H. Antitumour immunity regulated by aberrant ERBB family signalling. Nat. Rev. Cancer 21, 181–197 (2021).
doi: 10.1038/s41568-020-00322-0
Bassler, K., Schulte-Schrepping, J., Warnat-Herresthal, S., Aschenbrenner, A. C. & Schultze, J. L. The myeloid cell compartment-cell by cell. Annu. Rev. Immunol. 37, 269–293 (2019).
doi: 10.1146/annurev-immunol-042718-041728
Jaillon, S. et al. Neutrophil diversity and plasticity in tumour progression and therapy. Nat. Rev. Cancer 20, 485–503 (2020).
doi: 10.1038/s41568-020-0281-y
Wculek, S. K. et al. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 20, 7–24 (2020).
doi: 10.1038/s41577-019-0210-z
Lichterman, J. N. & Reddy, S. M. Mast cells: a new frontier for cancer immunotherapy. Cells 10, 2170 (2021).
doi: 10.3390/cells10061270
Marone, G. et al. Is there a role for basophils in cancer? Front. Immunol. 11, 2103 (2020).
doi: 10.3389/fimmu.2020.02103
Varricchi, G. et al. Eosinophils: the unsung heroes in cancer? Oncoimmunology 7, e1393134 (2018).
doi: 10.1080/2162402X.2017.1393134
Akashi, K., Traver, D., Miyamoto, T. & Weissman, I. L. A clonogenic common myeloid progenitor that gives rise to all myeloid lineages. Nature 404, 193–197 (2000).
doi: 10.1038/35004599
Orkin, S. H. & Zon, L. I. Hematopoiesis: an evolving paradigm for stem cell biology. Cell 132, 631–644 (2008).
doi: 10.1016/j.cell.2008.01.025
Drissen, R. et al. Distinct myeloid progenitor-differentiation pathways identified through single-cell RNA sequencing. Nat. Immunol. 17, 666–676 (2016).
doi: 10.1038/ni.3412
Kwok, I. et al. Combinatorial single-cell analyses of granulocyte-monocyte progenitor heterogeneity reveals an early uni-potent neutrophil progenitor. Immunity 53, 303–318 (2020).
doi: 10.1016/j.immuni.2020.06.005
Merad, M., Sathe, P., Helft, J., Miller, J. & Mortha, A. The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting. Annu. Rev. Immunol. 31, 563–604 (2013).
doi: 10.1146/annurev-immunol-020711-074950
Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656–661 (2010).
doi: 10.1126/science.1178331
Gomez Perdiguero, E. et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature 518, 547–551 (2015).
doi: 10.1038/nature13989
Wang, P. F. et al. Prognostic role of pretreatment circulating MDSCs in patients with solid malignancies: a meta-analysis of 40 studies. Oncoimmunology 7, e1494113 (2018).
doi: 10.1080/2162402X.2018.1494113
Veglia, F., Sanseviero, E. & Gabrilovich, D. I. Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat. Rev. Immunol. 21, 485–498 (2021).
doi: 10.1038/s41577-020-00490-y
Bronte, V. et al. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun. 7, 12150 (2016).
doi: 10.1038/ncomms12150
Bergenfelz, C. & Leandersson, K. The generation and identity of human myeloid-derived suppressor cells. Front. Oncol. 10, 109 (2020).
doi: 10.3389/fonc.2020.00109
Pathria, P., Louis, T. L. & Varner, J. A. Targeting tumor-associated macrophages in cancer. Trends Immunol. 40, 310–327 (2019).
doi: 10.1016/j.it.2019.02.003
Lopez-Yrigoyen, M., Cassetta, L. & Pollard, J. W. Macrophage targeting in cancer. Ann. N. Y. Acad. Sci. 1499, 18–41 (2021).
doi: 10.1111/nyas.14377
Cheng, S. et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells. Cell 184, 792–809 (2021). This study characterizes the diversity of intratumoural myeloid cell subsets in 210 patients across 15 human cancers.
doi: 10.1016/j.cell.2021.01.010
Ochocka, N. et al. Single-cell RNA sequencing reveals functional heterogeneity of glioma-associated brain macrophages. Nat. Commun. 12, 1151 (2021).
doi: 10.1038/s41467-021-21407-w
Li, B. H., Garstka, M. A. & Li, Z. F. Chemokines and their receptors promoting the recruitment of myeloid-derived suppressor cells into the tumor. Mol. Immunol. 117, 201–215 (2020).
doi: 10.1016/j.molimm.2019.11.014
Cannarile, M. A. et al. Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy. J. Immunother. Cancer 5, 53 (2017).
doi: 10.1186/s40425-017-0257-y
Eckert, F. et al. Potential role of CXCR4 targeting in the context of radiotherapy and immunotherapy of cancer. Front. Immunol. 9, 3018 (2018).
doi: 10.3389/fimmu.2018.03018
Logtenberg, M. E. W., Scheeren, F. A. & Schumacher, T. N. The CD47-SIRPalpha immune checkpoint. Immunity 52, 742–752 (2020).
doi: 10.1016/j.immuni.2020.04.011
Barkal, A. A. et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature 572, 392–396 (2019). This study identifies CD24 as a novel ‘don’t eat me’ signal expressed by tumour cells, which interacts with SIGLEC10 on macrophages to inhibit phagocytosis. Inhibition of this interaction improves the response to immunotherapy.
doi: 10.1038/s41586-019-1456-0
Advani, R. et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N. Engl. J. Med. 379, 1711–1721 (2018).
doi: 10.1056/NEJMoa1807315
Fisher, G. A. et al. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. J. Clin. Oncol. 38, 114–114 (2020).
doi: 10.1200/JCO.2020.38.4_suppl.114
Barkal, A. A. et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nat. Immunol. 19, 76–84 (2018).
doi: 10.1038/s41590-017-0004-z
Kamber, R. A. et al. Inter-cellular CRISPR screens reveal regulators of cancer cell phagocytosis. Nature 597, 549–554 (2021).
doi: 10.1038/s41586-021-03879-4
Shekarian, T. et al. Pattern recognition receptors: immune targets to enhance cancer immunotherapy. Ann. Oncol. 28, 1756–1766 (2017).
doi: 10.1093/annonc/mdx179
Liljenfeldt, L., Dieterich, L. C., Dimberg, A., Mangsbo, S. M. & Loskog, A. S. CD40L gene therapy tilts the myeloid cell profile and promotes infiltration of activated T lymphocytes. Cancer Gene Ther. 21, 95–102 (2014).
doi: 10.1038/cgt.2014.2
Vonderheide, R. H. CD40 agonist antibodies in cancer immunotherapy. Annu. Rev. Med. 71, 47–58 (2020).
doi: 10.1146/annurev-med-062518-045435
Sato-Kaneko, F. et al. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. JCI Insight 2, e93397 (2017).
doi: 10.1172/jci.insight.93397
Wang, S. et al. Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+ T cells. Proc. Natl Acad. Sci. USA 113, E7240–E7249 (2016).
doi: 10.1073/pnas.1608555113
Jing, W. et al. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models. J. Immunother. Cancer 7, 115 (2019).
doi: 10.1186/s40425-019-0573-5
Humeau, J., Le Naour, J., Galluzzi, L., Kroemer, G. & Pol, J. G. Trial watch: intratumoral immunotherapy. Oncoimmunology 10, 1984677 (2021).
doi: 10.1080/2162402X.2021.1984677
Sun, L. et al. Activating a collaborative innate-adaptive immune response to control metastasis. Cancer Cell 39, 1361–1374 (2021).
doi: 10.1016/j.ccell.2021.08.005
Li, D. K. & Wang, W. Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies. Oncol. Lett. 20, 176 (2020).
Le Naour, J., Zitvogel, L., Galluzzi, L., Vacchelli, E. & Kroemer, G. Trial watch: STING agonists in cancer therapy. Oncoimmunology 9, 1777624 (2020).
doi: 10.1080/2162402X.2020.1777624
Reni, M. APX005M, a CD40 monoclonal antibody, for patients with pancreatic adenocarcinoma. Lancet Oncol. 22, 10–11 (2021).
doi: 10.1016/S1470-2045(20)30724-5
Gocher, A. M., Workman, C. J. & Vignali, D. A. A. Interferon-gamma: teammate or opponent in the tumour microenvironment? Nat. Rev. Immunol. 22, 158–172 (2022).
doi: 10.1038/s41577-021-00566-3
Boukhaled, G. M., Harding, S. & Brooks, D. G. Opposing roles of type I interferons in cancer immunity. Annu. Rev. Pathol. 16, 167–198 (2021).
doi: 10.1146/annurev-pathol-031920-093932
Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
doi: 10.1016/j.celrep.2017.04.031
Bald, T. et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov. 4, 674–687 (2014).
doi: 10.1158/2159-8290.CD-13-0458
Chen, B. et al. Interferon-induced IDO1 mediates radiation resistance and is a therapeutic target in colorectal cancer. Cancer Immunol. Res. 8, 451–464 (2020).
doi: 10.1158/2326-6066.CIR-19-0282
Jacquelot, N. et al. Sustained type I interferon signaling as a mechanism of resistance to PD-1 blockade. Cell Res. 29, 846–861 (2019). This study demonstrates that sustained type I interferon signalling induced acquired resistance to anti-PD1 therapy in patients with melanoma.
doi: 10.1038/s41422-019-0224-x
Urban-Wojciuk, Z. et al. The role of TLRs in anti-cancer immunity and tumor rejection. Front. Immunol. 10, 2388 (2019).
doi: 10.3389/fimmu.2019.02388
Ravetch, J. V. & Lanier, L. L. Immune inhibitory receptors. Science 290, 84–89 (2000).
doi: 10.1126/science.290.5489.84
Cheng, X. et al. Systematic pan-cancer analysis identifies TREM2 as an immunological and prognostic biomarker. Front. Immunol. 12, 646523 (2021).
doi: 10.3389/fimmu.2021.646523
Georgoudaki, A. M. et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15, 2000–2011 (2016).
doi: 10.1016/j.celrep.2016.04.084
Kzhyshkowska, J., Gratchev, A. & Goerdt, S. Stabilin-1, a homeostatic scavenger receptor with multiple functions. J. Cell Mol. Med. 10, 635–649 (2006).
doi: 10.1111/j.1582-4934.2006.tb00425.x
La Fleur, L. et al. Targeting MARCO and IL37R on immunosuppressive macrophages in lung cancer blocks regulatory T cells and supports cytotoxic lymphocyte function. Cancer Res. 81, 956–967 (2021).
doi: 10.1158/0008-5472.CAN-20-1885
Eisinger, S. et al. Targeting a scavenger receptor on tumor-associated macrophages activates tumor cell killing by natural killer cells. Proc. Natl Acad. Sci. USA 117, 32005–32016 (2020).
doi: 10.1073/pnas.2015343117
Palani, S., Elima, K., Ekholm, E., Jalkanen, S. & Salmi, M. Monocyte stabilin-1 suppresses the activation of Th1 lymphocytes. J. Immunol. 196, 115–123 (2016).
doi: 10.4049/jimmunol.1500257
Viitala, M. et al. Immunotherapeutic blockade of macrophage Clever-1 reactivates the CD8(+) T-cell response against immunosuppressive tumors. Clin. Cancer Res. 25, 3289–3303 (2019).
doi: 10.1158/1078-0432.CCR-18-3016
Ammar, A. et al. Lymphatic expression of CLEVER-1 in breast cancer and its relationship with lymph node metastasis. Anal. Cell Pathol. 34, 67–78 (2011).
doi: 10.1155/2011/291769
Tadayon, S. et al. Lymphatic endothelial cell activation and dendritic cell transmigration is modified by genetic deletion of Clever-1. Front. Immunol. 12, 602122 (2021).
doi: 10.3389/fimmu.2021.602122
Algars, A. et al. Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients. Int. J. Cancer 131, 864–873 (2012).
doi: 10.1002/ijc.26457
Katzenelenbogen, Y. et al. Coupled scRNA-seq and intracellular protein activity reveal an immunosuppressive role of TREM2 in cancer. Cell 182, 872–885 (2020).
doi: 10.1016/j.cell.2020.06.032
Molgora, M. et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy. Cell 182, 886–900 (2020). This study highlights the role of TREM2 expressed by intratumoural macrophages in creating an immunosuppressive intratumoural milieu leading to resistance to anti-PD1 therapy.
doi: 10.1016/j.cell.2020.07.013
Chen, H. M. et al. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity. J. Clin. Invest. 128, 5647–5662 (2018).
doi: 10.1172/JCI97570
Sharma, N., Atolagbe, O. T., Ge, Z. & Allison, J. P. LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy. J. Exp. Med. 218, e20201811 (2021). This study demonstrates that LILRB4 expressed by TAMs is a novel checkpoint molecule and acts as a strong suppressor of antitumour immunity.
doi: 10.1084/jem.20201811
Guo, N. et al. Role and mechanism of LAIR-1 in the development of autoimmune diseases, tumors, and malaria: a review. Curr. Res. Transl. Med. 68, 119–124 (2020).
doi: 10.1016/j.retram.2020.05.003
Wang, J. et al. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. Nat. Med. 25, 656–666 (2019). This study describes the role of SIGLEC15 in suppressing antitumour immunity and establishes it as a potential immunotherapeutic target.
doi: 10.1038/s41591-019-0374-x
Xu, W. et al. Immune-checkpoint protein VISTA regulates antitumor immunity by controlling myeloid cell-mediated inflammation and immunosuppression. Cancer Immunol. Res. 7, 1497–1510 (2019).
doi: 10.1158/2326-6066.CIR-18-0489
Bono, P., Ekström, J., Karvonen, M. K., Mandelin, J. & Koivunen, J. Modelling treatment benefit for bexmarilimab (an anti-Clever-1 antibody and a novel macrophage checkpoint inhibitor) using phase I first-in-man trial data. J. Clin. Oncol. 39, e14530–e14530 (2021).
doi: 10.1200/JCO.2021.39.15_suppl.e14530
Jahchan, N. S. et al. Tuning the tumor myeloid microenvironment to fight cancer. Front. Immunol. 10, 1611 (2019).
doi: 10.3389/fimmu.2019.01611
Chaib, M., Chauhan, S. C. & Makowski, L. Friend or foe? recent strategies to target myeloid cells in cancer. Front. Cell Dev. Biol. 8, 351 (2020).
doi: 10.3389/fcell.2020.00351
Papadopoulos, K. P. et al. First-in-human study of AMG 820, a monoclonal anti-colony-stimulating factor 1 receptor antibody, in patients with advanced solid tumors. Clin. Cancer Res. 23, 5703–5710 (2017).
doi: 10.1158/1078-0432.CCR-16-3261
Razak, A. R. et al. Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors. J. Immunother. Cancer 8, e001006 (2020).
doi: 10.1136/jitc-2020-001006
Zhang, L. et al. Single-cell analyses inform mechanisms of myeloid-targeted therapies in colon cancer. Cell 181, 442–459 (2020). This study provides a comprehensive snapshot of major myeloid cell subsets and delineates the mechanistic basis of resistance to CSF1R blockade in colorectal cancer.
doi: 10.1016/j.cell.2020.03.048
Kumar, V. et al. Cancer-associated fibroblasts neutralize the anti-tumor effect of CSF1 receptor blockade by inducing PMN-MDSC infiltration of tumors. Cancer Cell 32, 654–668 (2017).
doi: 10.1016/j.ccell.2017.10.005
Gyori, D. et al. Compensation between CSF1R+ macrophages and Foxp3+ Treg cells drives resistance to tumor immunotherapy. JCI Insight 3, e120631 (2018).
doi: 10.1172/jci.insight.120631
Sun, L. et al. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 4, e126853 (2019).
doi: 10.1172/jci.insight.126853
Yuen, K. C. et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade. Nat. Med. 26, 693–698 (2020).
doi: 10.1038/s41591-020-0860-1
Schalper, K. A. et al. Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors. Nat. Med. 26, 688–692 (2020).
doi: 10.1038/s41591-020-0856-x
Kaneda, M. M. et al. PI3Kgamma is a molecular switch that controls immune suppression. Nature 539, 437–442 (2016).
doi: 10.1038/nature19834
De Henau, O. et al. Overcoming resistance to checkpoint blockade therapy by targeting PI3Kgamma in myeloid cells. Nature 539, 443–447 (2016).
doi: 10.1038/nature20554
Kaneda, M. M. et al. Macrophage PI3Kgamma drives pancreatic ductal adenocarcinoma progression. Cancer Discov. 6, 870–885 (2016).
doi: 10.1158/2159-8290.CD-15-1346
Mackert, J. R. et al. Dual negative roles of C/EBPalpha in the expansion and pro-tumor functions of MDSCs. Sci. Rep. 7, 14048 (2017).
doi: 10.1038/s41598-017-12968-2
Reebye, V. et al. Gene activation of CEBPA using saRNA: preclinical studies of the first in human saRNA drug candidate for liver cancer. Oncogene 37, 3216–3228 (2018).
doi: 10.1038/s41388-018-0126-2
Hashimoto, A. et al. Abstract 1730: up-regulation of C/EBPα inhibits suppressive activity of myeloid cells and potentiates antitumor response in mice and cancer patients. Cancer Res. 81, 1730–1730 (2021).
doi: 10.1158/1538-7445.AM2021-1730
Li, T. et al. c-Rel is a myeloid checkpoint for cancer immunotherapy. Nat. Cancer 1, 507–517 (2020).
doi: 10.1038/s43018-020-0061-3
Kortylewski, M. et al. Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment. Cancer Cell 15, 114–123 (2009).
doi: 10.1016/j.ccr.2008.12.018
Kortylewski, M. et al. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 11, 1314–1321 (2005).
doi: 10.1038/nm1325
Yu, H., Lee, H., Herrmann, A., Buettner, R. & Jove, R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 14, 736–746 (2014).
doi: 10.1038/nrc3818
Su, Y. L., Banerjee, S., White, S. V. & Kortylewski, M. STAT3 in tumor-associated myeloid cells: multitasking to disrupt immunity. Int. J. Mol. Sci. 19, 1803 (2018).
doi: 10.3390/ijms19061803
Abad, C. et al. Targeted STAT3 disruption in myeloid cells alters immunosuppressor cell abundance in a murine model of spontaneous medulloblastoma. J. Leukoc. Biol. 95, 357–367 (2014).
doi: 10.1189/jlb.1012531
Calcinotto, A. et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature 559, 363–369 (2018).
doi: 10.1038/s41586-018-0266-0
Zou, S. et al. Targeting STAT3 in cancer immunotherapy. Mol. Cancer 19, 145 (2020).
doi: 10.1186/s12943-020-01258-7
Beebe, J. D., Liu, J. Y. & Zhang, J. T. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we? Pharmacol. Ther. 191, 74–91 (2018).
doi: 10.1016/j.pharmthera.2018.06.006
Marigo, I. et al. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor. Immunity 32, 790–802 (2010).
doi: 10.1016/j.immuni.2010.05.010
Larionova, I., Kazakova, E., Patysheva, M. & Kzhyshkowska, J. Transcriptional, epigenetic and metabolic programming of tumor-associated macrophages. Cancers 12, 1411 (2020).
doi: 10.3390/cancers12061411
Amit, I., Winter, D. R. & Jung, S. The role of the local environment and epigenetics in shaping macrophage identity and their effect on tissue homeostasis. Nat. Immunol. 17, 18–25 (2016).
doi: 10.1038/ni.3325
Baylin, S. B. & Jones, P. A. A decade of exploring the cancer epigenome - biological and translational implications. Nat. Rev. Cancer 11, 726–734 (2011).
doi: 10.1038/nrc3130
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R. & Baylin, S. B. The emerging role of epigenetic therapeutics in immuno-oncology. Nat. Rev. Clin. Oncol. 17, 75–90 (2020).
doi: 10.1038/s41571-019-0266-5
Guerriero, J. L. et al. Class IIa HDAC inhibition reduces breast tumours and metastases through anti-tumour macrophages. Nature 543, 428–432 (2017).
doi: 10.1038/nature21409
Lodewijk, I. et al. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy. Clin. Epigenetics 13, 63 (2021).
doi: 10.1186/s13148-021-01046-0
Lu, Z. et al. Epigenetic therapy inhibits metastases by disrupting premetastatic niches. Nature 579, 284–290 (2020). Adjuvant epigenetic therapy with low-dose DNA methyltransferase and histone deacetylase inhibitors 5-azacytidine and entinostat inhibits premetastatic niche formation by MDSCs.
doi: 10.1038/s41586-020-2054-x
Mohapatra, S., Pioppini, C., Ozpolat, B. & Calin, G. A. Non-coding RNAs regulation of macrophage polarization in cancer. Mol. Cancer 20, 24 (2021).
doi: 10.1186/s12943-021-01313-x
Obaid, M., Udden, S. M. N., Alluri, P. & Mandal, S. S. LncRNA HOTAIR regulates glucose transporter Glut1 expression and glucose uptake in macrophages during inflammation. Sci. Rep. 11, 232 (2021).
doi: 10.1038/s41598-020-80291-4
Basavarajappa, D. et al. Dicer up-regulation by inhibition of specific proteolysis in differentiating monocytic cells. Proc. Natl Acad. Sci. USA 117, 8573–8583 (2020).
doi: 10.1073/pnas.1916249117
Goswami, S. et al. Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. J. Clin. Invest. 128, 3813–3818 (2018).
doi: 10.1172/JCI99760
Labani-Motlagh, A., Ashja-Mahdavi, M. & Loskog, A. The tumor microenvironment: a milieu hindering and obstructing antitumor immune responses. Front. Immunol. 11, 940 (2020).
doi: 10.3389/fimmu.2020.00940
Vitale, I., Manic, G., Coussens, L. M., Kroemer, G. & Galluzzi, L. Macrophages and metabolism in the tumor microenvironment. Cell Metab. 30, 36–50 (2019).
doi: 10.1016/j.cmet.2019.06.001
Kumar, V., Patel, S., Tcyganov, E. & Gabrilovich, D. I. The nature of myeloid-derived suppressor cells in the tumor microenvironment. Trends Immunol. 37, 208–220 (2016).
doi: 10.1016/j.it.2016.01.004
Morello, S., Pinto, A., Blandizzi, C. & Antonioli, L. Myeloid cells in the tumor microenvironment: role of adenosine. Oncoimmunology 5, e1108515 (2016).
doi: 10.1080/2162402X.2015.1108515
Nguyen, N. T. et al. Aryl hydrocarbon receptor negatively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc. Natl Acad. Sci. USA 107, 19961–19966 (2010).
doi: 10.1073/pnas.1014465107
Colegio, O. R. et al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature 513, 559–563 (2014).
doi: 10.1038/nature13490
Liu, P. S. et al. alpha-ketoglutarate orchestrates macrophage activation through metabolic and epigenetic reprogramming. Nat. Immunol. 18, 985–994 (2017).
doi: 10.1038/ni.3796
Oh, M. H. et al. Targeting glutamine metabolism enhances tumor-specific immunity by modulating suppressive myeloid cells. J. Clin. Invest. 130, 3865–3884 (2020).
doi: 10.1172/JCI131859
Cali, B. et al. GM-CSF nitration is a new driver of myeloid suppressor cell activity in tumors. Front. Immunol. 12, 718098 (2021).
doi: 10.3389/fimmu.2021.718098
Mijatovic, S. et al. The double-faced role of nitric oxide and reactive oxygen species in solid tumors. Antioxidants 9, 374 (2020).
doi: 10.3390/antiox9050374
Fionda, C., Abruzzese, M. P., Santoni, A. & Cippitelli, M. Immunoregulatory and effector activities of nitric oxide and reactive nitrogen species in cancer. Curr. Med. Chem. 23, 2618–2636 (2016).
doi: 10.2174/0929867323666160727105101
Goswami, S. et al. Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat. Med. 26, 39–46 (2020). This study highlights the role of CD73-expressing TAMs in resistance to anti-PD1 therapy for glioblastoma.
doi: 10.1038/s41591-019-0694-x
Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13, 412–424 (2015).
doi: 10.1016/j.celrep.2015.08.077
Campesato, L. F. et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-kynurenine. Nat. Commun. 11, 4011 (2020).
doi: 10.1038/s41467-020-17750-z
Zelenay, S. et al. Cyclooxygenase-dependent tumor growth through evasion of immunity. Cell 162, 1257–1270 (2015).
doi: 10.1016/j.cell.2015.08.015
Lu, G. et al. Myeloid cell-derived inducible nitric oxide synthase suppresses M1 macrophage polarization. Nat. Commun. 6, 6676 (2015).
doi: 10.1038/ncomms7676
Vigano, S. et al. Targeting adenosine in cancer immunotherapy to enhance T-cell function. Front. Immunol. 10, 925 (2019).
doi: 10.3389/fimmu.2019.00925
Tang, K., Wu, Y. H., Song, Y. & Yu, B. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy. J. Hematol. Oncol. 14, 68 (2021).
doi: 10.1186/s13045-021-01080-8
Pu, D. et al. Cyclooxygenase-2 inhibitor: a potential combination strategy with immunotherapy in cancer. Front. Oncol. 11, 637504 (2021).
doi: 10.3389/fonc.2021.637504
Xu, M. et al. Arachidonic acid metabolism controls macrophage alternative activation through regulating oxidative phosphorylation in PPARgamma dependent manner. Front. Immunol. 12, 618501 (2021).
doi: 10.3389/fimmu.2021.618501
Liang, W. & Ferrara, N. Iron metabolism in the tumor microenvironment: contributions of innate immune cells. Front. Immunol. 11, 626812 (2020).
doi: 10.3389/fimmu.2020.626812
Reinfeld, B. I. et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature 593, 282–288 (2021).
doi: 10.1038/s41586-021-03442-1
Larionova, I., Kazakova, E., Gerashchenko, T. & Kzhyshkowska, J. New angiogenic regulators produced by TAMs: perspective for targeting tumor angiogenesis. Cancers 13, 3253 (2021).
doi: 10.3390/cancers13133253
De Palma, M., Biziato, D. & Petrova, T. V. Microenvironmental regulation of tumour angiogenesis. Nat. Rev. Cancer 17, 457–474 (2017).
doi: 10.1038/nrc.2017.51
Steitz, A. M. et al. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C. Cell Death Dis. 11, 249 (2020).
doi: 10.1038/s41419-020-2438-8
Ferrara, N. & Adamis, A. P. Ten years of anti-vascular endothelial growth factor therapy. Nat. Rev. Drug Discov. 15, 385–403 (2016).
doi: 10.1038/nrd.2015.17
Dalton, H. J. et al. Macrophages facilitate resistance to Anti-VEGF therapy by altered VEGFR expression. Clin. Cancer Res. 23, 7034–7046 (2017).
doi: 10.1158/1078-0432.CCR-17-0647
Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695–709 (2013).
doi: 10.1016/j.ccr.2013.11.007
Shojaei, F. et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc. Natl Acad. Sci. USA 106, 6742–6747 (2009).
doi: 10.1073/pnas.0902280106
Fu, L. Q. et al. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 353, 104119 (2020).
doi: 10.1016/j.cellimm.2020.104119
Hughes, R. et al. Perivascular M2 macrophages stimulate tumor relapse after chemotherapy. Cancer Res. 75, 3479–3491 (2015).
doi: 10.1158/0008-5472.CAN-14-3587
Kozin, S. V. et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res. 70, 5679–5685 (2010).
doi: 10.1158/0008-5472.CAN-09-4446
Kloepper, J. et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc. Natl Acad. Sci. USA 113, 4476–4481 (2016).
doi: 10.1073/pnas.1525360113
Chiu, D. K. et al. Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. Nat. Commun. 8, 517 (2017).
doi: 10.1038/s41467-017-00530-7
Henze, A. T. & Mazzone, M. The impact of hypoxia on tumor-associated macrophages. J. Clin. Invest. 126, 3672–3679 (2016).
doi: 10.1172/JCI84427
Dumond, A. & Pages, G. Neuropilins, as relevant oncology target: their role in the tumoral microenvironment. Front. Cell Dev. Biol. 8, 662 (2020).
doi: 10.3389/fcell.2020.00662
Wenes, M. et al. Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis. Cell Metab. 24, 701–715 (2016).
doi: 10.1016/j.cmet.2016.09.008
Park, J. E. et al. Hypoxia-induced tumor exosomes promote M2-like macrophage polarization of infiltrating myeloid cells and microRNA-mediated metabolic shift. Oncogene 38, 5158–5173 (2019).
doi: 10.1038/s41388-019-0782-x
June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64–73 (2018).
doi: 10.1056/NEJMra1706169
Morotti, M. et al. Promises and challenges of adoptive T-cell therapies for solid tumours. Br. J. Cancer 124, 1759–1776 (2021).
doi: 10.1038/s41416-021-01353-6
Shi, L. Z. et al. Blockade of CTLA-4 and PD-1 enhances adoptive T-cell therapy efficacy in an ICOS-mediated manner. Cancer Immunol. Res. 7, 1803–1812 (2019).
doi: 10.1158/2326-6066.CIR-18-0873
Perez, C. R. & De Palma, M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat. Commun. 10, 5408 (2019).
doi: 10.1038/s41467-019-13368-y
Salah, A. et al. Insights into dendritic cells in cancer immunotherapy: from bench to clinical applications. Front. Cell Dev. Biol. 9, 686544 (2021).
doi: 10.3389/fcell.2021.686544
Andreesen, R. et al. Adoptive transfer of tumor cytotoxic macrophages generated in vitro from circulating blood monocytes: a new approach to cancer immunotherapy. Cancer Res. 50, 7450–7456 (1990).
Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947–953 (2020).
doi: 10.1038/s41587-020-0462-y
Anderson, N. R., Minutolo, N. G., Gill, S. & Klichinsky, M. Macrophage-based approaches for cancer immunotherapy. Cancer Res. 81, 1201–1208 (2021).
doi: 10.1158/0008-5472.CAN-20-2990
Velazquez, E. et al. Abstract 2563: macrophage Toll-like receptor-chimeric antigen receptors (MOTO-CARs) as a novel adoptive cell therapy for the treatment of solid malignancies. Cancer Res. 78, 2563–2563 (2018).
doi: 10.1158/1538-7445.AM2018-2563
Lucas, K. G., Bao, L., Bruggeman, R., Dunham, K. & Specht, C. The detection of CMV pp65 and IE1 in glioblastoma multiforme. J. Neurooncol 103, 231–238 (2011).
doi: 10.1007/s11060-010-0383-6
Zhou, D. et al. Lamp-2a facilitates MHC class II presentation of cytoplasmic antigens. Immunity 22, 571–581 (2005).
doi: 10.1016/j.immuni.2005.03.009
Brempelis, K. J. et al. Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses. J. Immunother. Cancer 8, e001356 (2020).
doi: 10.1136/jitc-2020-001356
Kaczanowska, S. et al. Genetically engineered myeloid cells rebalance the core immune suppression program in metastasis. Cell 184, 2033–2052 e2021 (2021). This study demonstrates the ability of IL-12-expressing genetically engineered myeloid cells to reverse immunosuppression in the premetastatic niche.
doi: 10.1016/j.cell.2021.02.048
Moi, D., Wilson, E., Weinert, D., Chiaretti, S. & Mazzieri, R. Adoptive transfer of genetically engineered monocytes for the tumour targeted delivery of IFN-alpha. Cytotherapy 20, S18–S19 (2018).
doi: 10.1016/j.jcyt.2018.02.038
Shields, C. W. T. et al. Cellular backpacks for macrophage immunotherapy. Sci. Adv. 6, eaaz6579 (2020).
doi: 10.1126/sciadv.aaz6579
Neophytou, C. M. et al. The role of tumor-associated myeloid cells in modulating cancer therapy. Front. Oncol. 10, 899 (2020).
doi: 10.3389/fonc.2020.00899
Sakai, Y. et al. Distinct chemotherapy-associated anti-cancer immunity by myeloid cells inhibition in murine pancreatic cancer models. Cancer Sci. 110, 903–912 (2019).
doi: 10.1111/cas.13944
Mitchem, J. B. et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 73, 1128–1141 (2013).
doi: 10.1158/0008-5472.CAN-12-2731
Mantovani, A., Marchesi, F., Malesci, A., Laghi, L. & Allavena, P. Tumour-associated macrophages as treatment targets in oncology. Nat. Rev. Clin. Oncol. 14, 399–416 (2017).
doi: 10.1038/nrclinonc.2016.217
Wu, C. et al. Tumor microenvironment following gemcitabine treatment favors differentiation of immunosuppressive Ly6C
doi: 10.4049/jimmunol.1900930
Cunha, L. D. et al. LC3-associated phagocytosis in myeloid cells promotes tumor immune tolerance. Cell 175, 429–441 e416 (2018). This study highlights the role of LC3-associated autophagy in intratumoural macrophages in immunosuppression and tumour growth.
doi: 10.1016/j.cell.2018.08.061
Roy, S. et al. Macrophage-derived neuropilin-2 exhibits novel tumor-promoting functions. Cancer Res. 78, 5600–5617 (2018).
doi: 10.1158/0008-5472.CAN-18-0562
Seifert, L. et al. Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice. Gastroenterology 150, 1659–1672 e1655 (2016).
doi: 10.1053/j.gastro.2016.02.070
Frey, B., Hehlgans, S., Rodel, F. & Gaipl, U. S. Modulation of inflammation by low and high doses of ionizing radiation: implications for benign and malign diseases. Cancer Lett. 368, 230–237 (2015).
doi: 10.1016/j.canlet.2015.04.010
Ren, H. et al. Augmentation of innate immunity by low-dose irradiation. Cell Immunol. 244, 50–56 (2006).
doi: 10.1016/j.cellimm.2007.02.009
Klug, F. et al. Low-dose irradiation programs macrophage differentiation to an iNOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy. Cancer Cell 24, 589–602 (2013).
doi: 10.1016/j.ccr.2013.09.014
Akkari, L. et al. Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci. Transl. Med. 12, eaaw7843 (2020).
doi: 10.1126/scitranslmed.aaw7843
Bian, Z. et al. Intratumoral SIRPalpha-deficient macrophages activate tumor antigen-specific cytotoxic T cells under radiotherapy. Nat. Commun. 12, 3229 (2021).
doi: 10.1038/s41467-021-23442-z
Liu, X., Hogg, G. D. & DeNardo, D. G. Rethinking immune checkpoint blockade: ‘beyond the T cell’. J. Immunother. Cancer 9, e001460 (2021).
doi: 10.1136/jitc-2020-001460
Weissleder, R. & Pittet, M. J. The expanding landscape of inflammatory cells affecting cancer therapy. Nat. Biomed. Eng. 4, 489–498 (2020).
doi: 10.1038/s41551-020-0524-y
Biswas, S. K. & Mantovani, A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat. Immunol. 11, 889–896 (2010).
doi: 10.1038/ni.1937
Gao, J. et al. VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer. Nat. Med. 23, 551–555 (2017).
doi: 10.1038/nm.4308
Li, T. et al. Targeting MDSC for immune-checkpoint blockade in cancer immunotherapy: current progress and new prospects. Clin. Med. Insights Oncol. 15, 11795549211035540 (2021).
doi: 10.1177/11795549211035540
Hou, A., Hou, K., Huang, Q., Lei, Y. & Chen, W. Targeting myeloid-derived suppressor cell, a promising strategy to overcome resistance to immune checkpoint inhibitors. Front. Immunol. 11, 783 (2020).
doi: 10.3389/fimmu.2020.00783
Cassetta, L. & Kitamura, T. Targeting tumor-associated macrophages as a potential strategy to enhance the response to immune checkpoint inhibitors. Front. Cell Dev. Biol. 6, 38 (2018).
doi: 10.3389/fcell.2018.00038
Chevrier, S. et al. An immune atlas of clear cell renal cell carcinoma. Cell 169, 736–749 (2017).
doi: 10.1016/j.cell.2017.04.016
Qu, Y. et al. Baseline frequency of inflammatory Cxcl9-expressing tumor-associated macrophages predicts response to avelumab treatment. Cell Rep. 32, 107873 (2020).
doi: 10.1016/j.celrep.2020.107873
Lee, J. B., Ha, S. J. & Kim, H. R. Clinical insights into novel immune checkpoint inhibitors. Front. Pharmacol. 12, 681320 (2021).
doi: 10.3389/fphar.2021.681320
Anderson, A. C., Joller, N. & Kuchroo, V. K. Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44, 989–1004 (2016).
doi: 10.1016/j.immuni.2016.05.001
Yan, J. & Horng, T. Lipid metabolism in regulation of macrophage functions. Trends Cell Biol. 30, 979–989 (2020).
doi: 10.1016/j.tcb.2020.09.006
Lam, K. C. et al. Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment. Cell 184, 5338–5356 (2021). This study delineates the mechanistic basis of microbiota-induced type I interferon responses to enhance sensitivity to anti-PD1 therapy.
doi: 10.1016/j.cell.2021.09.019
Tian, X., Shen, H., Li, Z., Wang, T. & Wang, S. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. J. Hematol. Oncol. 12, 84 (2019).
doi: 10.1186/s13045-019-0772-z
Gubin, M. M. et al. High-dimensional analysis delineates myeloid and lymphoid compartment remodeling during successful immune-checkpoint cancer therapy. Cell 175, 1014–1030 (2018).
doi: 10.1016/j.cell.2018.09.030
Pombo Antunes, A. R. et al. Single-cell profiling of myeloid cells in glioblastoma across species and disease stage reveals macrophage competition and specialization. Nat. Neurosci. 24, 595–610 (2021).
doi: 10.1038/s41593-020-00789-y
Casanova-Acebes, M. et al. Tissue-resident macrophages provide a pro-tumorigenic niche to early NSCLC cells. Nature 595, 578–584 (2021). This study highlights the role of tissue-resident macrophages in the development of early-stage lung cancer.
doi: 10.1038/s41586-021-03651-8
Lee, H., Na, K. J. & Choi, H. Differences in tumor immune microenvironment in metastatic sites of breast cancer. Front. Oncol. 11, 649004 (2021).
doi: 10.3389/fonc.2021.649004
Hofbauer, L. C. et al. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol. 18, 488–505 (2021).
doi: 10.1038/s41571-021-00499-9
Irvine, D. J. & Dane, E. L. Enhancing cancer immunotherapy with nanomedicine. Nat. Rev. Immunol. 20, 321–334 (2020).
doi: 10.1038/s41577-019-0269-6
Klebanoff, C. A., Gattinoni, L. & Restifo, N. P. CD8+T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211, 214–224 (2006).
doi: 10.1111/j.0105-2896.2006.00391.x
Okla, K., Farber, D. L. & Zou, W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J. Exp. Med. 218, e20201605 (2021).
doi: 10.1084/jem.20201605
Dai, H. et al. PIRs mediate innate myeloid cell memory to nonself MHC molecules. Science 368, 1122–1127 (2020). This study shows the ability of innate immune cells to mount a specific memory response to MHC class I antigens through A-type paired immunoglobulin-like receptors.
doi: 10.1126/science.aax4040
Anassi, E. & Ndefo, U. A. Sipuleucel-T (Provenge) injection: the first immunotherapy agent (vaccine) for hormone-refractory prostate cancer. Pharm. Ther. 36, 197–202 (2011).
Sabado, R. L., Balan, S. & Bhardwaj, N. Dendritic cell-based immunotherapy. Cell Res. 27, 74–95 (2017).
doi: 10.1038/cr.2016.157
Charles, J. et al. An innovative plasmacytoid dendritic cell line-based cancer vaccine primes and expands antitumor T-cells in melanoma patients in a first-in-human trial. Oncoimmunology 9, 1738812 (2020).
doi: 10.1080/2162402X.2020.1738812
Saxena, M. & Bhardwaj, N. Re-emergence of dendritic cell vaccines for cancer treatment. Trends Cancer 4, 119–137 (2018).
doi: 10.1016/j.trecan.2017.12.007
Harari, A., Graciotti, M., Bassani-Sternberg, M. & Kandalaft, L. E. Antitumour dendritic cell vaccination in a priming and boosting approach. Nat. Rev. Drug Discov. 19, 635–652 (2020).
doi: 10.1038/s41573-020-0074-8
Garg, A. D., Coulie, P. G., Van den Eynde, B. J. & Agostinis, P. Integrating next-generation dendritic cell vaccines into the current cancer immunotherapy landscape. Trends Immunol. 38, 577–593 (2017).
doi: 10.1016/j.it.2017.05.006
Belderbos, R. A., Aerts, J. & Vroman, H. Enhancing dendritic cell therapy in solid tumors with immunomodulating conventional treatment. Mol. Ther. Oncolytics 13, 67–81 (2019).
doi: 10.1016/j.omto.2019.03.007